Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR-Reference-Cited by-同舟云学术

Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR

Published:2017-05 Issue:3 Volume:16 Page:371-379
ISSN:1569-1993
Container-title:Journal of Cystic Fibrosis
language:en
Short-container-title:Journal of Cystic Fibrosis

Author:

Donaldson Scott H.,Solomon George M.,Zeitlin Pamela L.,Flume Patrick A.,Casey Alicia,McCoy Karen,Zemanick Edith T.,Mandagere Arun,Troha Janice M.,Shoemaker Steven A.,Chmiel James F.,Taylor-Cousar Jennifer L.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health

Reference29 articles.

1. Personalized medicine in cystic fibrosis: dawning of a new era;Clancy;Am J Respir Crit Care Med,2012

2. Correction of both NBD1 energetics and domain interface is required to restore DeltaF508 CFTR folding and function;Rabeh;Cell,2012

3. The cystic fibrosis-causing mutation deltaF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis;Thibodeau;J Biol Chem,2010

4. Searching for combinations of small-molecule correctors to restore f508del-cystic fibrosis transmembrane conductance regulator function and processing;Boinot;J Pharmacol Exp Ther,2014

5. Discovery of novel potent DeltaF508-CFTR correctors that target the nucleotide binding domain;Odolczyk;EMBO Mol Med,2013

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small molecule modulators of cystic fibrosis transmembrane conductance regulator (CFTR): Structure, classification, and mechanisms;European Journal of Medicinal Chemistry;2024-02

2. Cystic Fibrosis Modulator Therapies: Bridging Insights from CF to other Membrane Protein Misfolding Diseases;Israel Journal of Chemistry;2024-01-24

3. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)-Targeted Therapeutics for Cystic Fibrosis;Ion Channels as Targets in Drug Discovery;2024

4. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del);Cochrane Database of Systematic Reviews;2023-11-20

5. Cystic fibrosis and primary ciliary dyskinesia: Similarities and differences;Respiratory Medicine;2023-04